Navigation Links
Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial
Date:5/22/2008

LAS VEGAS, May 22 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) has entered into an agreement with Dr. H. Christopher Moore to be the sponsor and general partner of ProDerm Limited Partnership (PDLP) which will fund a minimum of $1 million and up to $10 million of the clinical development for CVBT's wound healing drug candidate.

"I am extremely impressed with CVBT's wound healing drug, which I believe has the potential to treat patients for diabetic ulcers and venous stasis leg wounds better than any of the current products on the market. The active pharmaceutical ingredient (API) is truly remarkable," said Dr. Moore.

PDLP will engage CVBT in a development agreement to conduct wound healing clinical trials. CVBT will pay a royalty to PDLP of 10% of revenues or other moneys received from the commercialization of the drug candidate up to a maximum of twenty times (20x) the funded amount of the development agreement in exchange for the intellectual property created. Daniel C. Montano, CVBT's President and CEO, has agreed to personally provide the individual partners of PDLP a "Put" to Mr. Montano for their interest in CDCP equal to 200% of their investment in PDLP less distributions paid from PDLP commencing 36 months and ending 60 months after their investment in PDLP.

"These clinical partnerships are very important to the timely development of CVBT's drug candidates. The ability to access the necessary funding for CVBT's FDA clinical trials through clinical partnerships during these uncertain times for the capital markets gives us the ability to move forward with our planned clinical development schedule," said Mr. Montano.

"CVBT now has two clinical partnerships in place supporting its trials through development agreements. The relative cost of capital and the minimal dilution to existing shareholders makes this financing vehicle an attractive alternative to selling equity and placing debt in the current capital markets environment," said Mickael A. Flaa, CFO of CVBT.

About Dr. H. Christopher Moore

Dr. H. Christopher Moore, M.D., F.A.C.S., has both a B.S. and a Medical degree from the University of Southern California. He is a Diplomate of both the American Board of Otolaryngology and the American board of Facial Plastic and Reconstructive Surgery. He has been a Professor of Surgery at the University of California, Irvine, and has been a frequent lecturer on Facial Plastic and Reconstructive Surgery throughout the U.S. Currently, Dr. Moore practices in Fullerton, CA.

Dr. Moore has independently owned and operated a successful outpatient surgery center in Fullerton. At this time, he is invested as a limited partner and serves on the Board of Directors of a large multi-specialty surgery center in Fullerton. He was also a founding member of Cryoport, Inc., a company that developed, manufactures and markets an ultra low temperature shipping device. Dr. Moore remains involved as a major shareholder in this company.

About CardioVascular BioTherapeutics, Inc.

CVBT is a biopharmaceutical company developing drug candidates formulated with human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetes and in patients suffering from peripheral artery disease of the legs. An additional proof-of-concept study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information please visit http://www.cvbt.com.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward-looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Media Contact:

Allison Caplan

CardioVascular BioTherapeutics, Inc.

(702) 839-7235

acaplan@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
2. Aung FootHealth Clinics & Advanced Wound Care Center Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Trial
3. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
4. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
5. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
6. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
7. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
8. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , February 24, 2017 Following ... Israel , s AMAR is a ... 250 M w ound care market in ... BST for inclusion in the National Health ... system   E-QURE Corp. (OTCQB: EQUR), a ...
(Date:2/24/2017)... -- Research and Markets has announced the addition of the ... their offering. ... research Hemophilia Drugs Price Analysis and Strategies - 2016, provides drug pricing ... the following questions: What are the key ... in the Global Hemophilia market? What are the unit ...
(Date:2/24/2017)... 2017 Medical information groups within the ... self-service capabilities to manage inquiries from external stakeholders ... New research from consulting leader Best Practices, LLC ... website portals where HCPs can sign on and ... many findings to emerge from the new study ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health ... British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition ... Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol treatment ...
(Date:2/26/2017)... TROY, MICHIGAN (PRWEB) , ... February 25, 2017 , ... ... leader Kim Jong-un, heightened awareness and concern over nerve agents and the deadly use ... on the human nervous system and how even small doses can be lethal. , ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby Products, an innovative ... it would be offering some it’s exclusive product line to the public through ... unique baby clothing/feeding products, will team up with AMAZON to distribute a limited ...
(Date:2/26/2017)... ... 26, 2017 , ... Functional imaging data supports improved cognition ... released today at the 1st Pan American Parkinson’s and Movement Disorders Congress. , ... in improving cognitive function in PD patients. This study, led by Ibarretxe-Bilbao et ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... on tooth replacement options at his office, Antoine Dental Center. Currently, patients can ... $18,499. Some restrictions may apply, but patients can learn more about these offers ...
Breaking Medicine News(10 mins):